Browsing Tag
Keytruda
62 posts
Gilead’s Trodelvy-Keytruda lung cancer combination misses Phase III endpoints despite higher response rate
Trodelvy plus Keytruda increased response rates and numerically lengthened progression-free survival in EVOKE-03, but the Phase III study failed its statistical endpoints and produced no overall survival advantage.
Akeso’s ivonescimab beats Keytruda on overall survival in China as Summit Therapeutics’ global wager gains another proof point
Akeso's HARMONi-2 trial reported median overall survival of 30.8 months for ivonescimab against 22.6 months for pembrolizumab, strengthening the scientific case while leaving global validation in Summit Therapeutics' territories as the crucial commercial test.
Moderna proposes $2bn zero-coupon notes as oncology success reshapes capital strategy
Moderna plans a $2 billion private placement of zero-regular-interest convertible notes due 2032, with a possible additional $300 million and capped-call protection designed to reduce dilution as the company prepares for increased oncology investment.
Merck (NYSE: MRK) reports Q2 loss, hikes revenue view as Keytruda Qlex ramps
Merck raised 2026 sales guidance to $67.3B but cut EPS to $2.76 on Terns charge. Lipfendra approval and $463M Keytruda Qlex quarter reshape the 2028 cliff.
Pfizer (PFE), Merck (MRK) win FDA expansion for Padcev plus Keytruda in all MIBC patients
Pfizer (PFE) Padcev+Keytruda MIBC label expands to all patients as first platinum-free regimen; AstraZeneca's Imfinzi cisplatin-only slot loses ground.
Merck (MRK) signs $510m AI drug discovery deal with Protillion Biosciences
Merck (MRK) signs a $510 million AI drug discovery deal with Protillion Biosciences, expanding its AI push ahead of the Keytruda patent cliff. Full analysis.
Moderna (MRNA) and Merck (MRK) cancer vaccine sustains benefit at five years, but investors stay cautious
Moderna and Merck's mRNA cancer vaccine sustained a 49% reduction in melanoma recurrence at five years, but MRNA fell as investors weigh near-term pressures.
Has Akeso Inc. just exposed the next weak spot in standard lung cancer treatment?
Find out how Akeso Inc.’s ivonescimab survival data could reshape lung cancer treatment and challenge PD-1 drug combinations.
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind
Erasca lost half its value on an IP challenge and a trial death. Now ASCO 2026 looms, Merck is on board, and traders are positioning before the verdict.